Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment

Conclusion: In the review, we described the significance of immunotherapy in the management of various types of cancer.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research

Related Links:

Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
iroshi Seno Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since most patients are diagnosed at advanced stage and the current systemic treatment options using molecular-targeted drugs remain unsatisfactory. However, the recent success of cancer immunotherapies has revolutionized the landscape of cancer therapy. Since HCC is characterized by metachronous multicentric occurrence, immunotherapies that induce systemic and durable responses could be an appealing treatment option. Despite the suppressive milieu of the liver and tumor immunosurveillance escape mechanisms, clinical studies...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractPurpose of reviewTo discuss invasive cardiovascular procedures as they relate to onco-cardiology, as well as recent additions to anti-cancer therapies and their subsequent effect on cardiovascular toxicity.Recent findingsThe development of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy has been linked to cardiotoxicity and represents an emerging area of concern. Recent advances in transcatheter valve replacement have shown benefits compared with surgical management regardless of malignancy type, stage, or treatment.SummaryWith the increasing use of immunotherapy and increasing recognition...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
. Chandra Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality. Identification of molecular mechanisms by which cancerous cells evade T cell-mediated cytotoxic damage has led to the modern era of immunotherapy in cancer treatment. Agents that release these immune brakes have shown activity to recover dysfunctional T cells and regress various cancer. Both cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death-1 (PD-1) play their role as physiologic brak...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ton The clinical success stories of chimeric antigen receptor (CAR)-T cell therapy against B-cell malignancies have contributed to immunotherapy being at the forefront of cancer therapy today. Their success has fueled interest in improving CAR constructs, identifying additional antigens to target, and clinically evaluating them across a wide range of malignancies. However, along with the exciting potential of CAR-T therapy comes the real possibility of serious side effects. While the FDA has approved commercialized CAR-T cell therapy, challenges associated with manufacturing, costs, and related toxicities have resulted...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract Accumulating evidences have demonstrated that the existence of breast cancer-initiating cells, which drives the original tumorigenicity, local invasion and migration propensity of breast cancer. These cells, termed as breast cancer stem cells (BCSCs), possess properties including self-renewal, multidirectional differentiation and proliferative potential, and are believed to play important roles in the intrinsic drug resistance of breast cancer. One of the reasons why BCBCs cause difficulties in breast cancer treating is that BCBCs can control both genetic and non-genetic elements to keep their niches safe...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
A highly expressed prostaglandin E2 (PGE2) in tumor tissues suppresses antitumor immunity in the tumor microenvironment (TME) and causes tumor immune evasion leading to disease progression. In animal studies, selective inhibition of the prostaglandin E receptor 4 (EP4), one of four PGE2 receptors, suppresses tumor growth, restoring the tumor immune response toward an antitumorigenic condition. This review summarizes PGE2/EP4 signal inhibition in relation to the cancer-immunity cycle (C-IC), which describes fundamental tumor-immune interactions in cancer immunotherapy. PGE2 is suggested to slow down C-IC by inhibiting natur...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Researchers at the University of Texas Southwestern Medical Center and University of Chicago have discovered that bacteria that usually live in the gut can accumulate in tumors and improve the effectiveness of immunotherapy in mice. The study, which will be published March 6 in the Journal of Experimental Medicine (JEM), suggests that
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
(Rockefeller University Press) Researchers at the University of Texas Southwestern Medical Center and University of Chicago have discovered that bacteria that usually live in the gut can accumulate in tumors and improve the effectiveness of immunotherapy in mice. The study, which will be published March 6 in the Journal of Experimental Medicine (JEM), suggests that treating cancer patients with Bifidobacteria might boost their response to CD47 immunotherapy, a wide-ranging anti-cancer treatment that is currently being evaluated in several clinical trials.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This event brings together clinicians from multiple disciplines and basic research scientists to discuss the latest findings on how autoimmunity impacts the latest approaches in immunotherapy to treat cancer. Clinical trials will be highlighted and the development of unexpected autoimmunity will be discussed in the context of the approaches that are being currently utilized for cancer therapy.Air date: 3/23/2020 8:00:00 AM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
More News: Cancer | Cancer & Oncology | Cancer Therapy | Databases & Libraries | Immunotherapy